Aug 15
Opportunity
Patients are experts in their condition and should inform clinical development. Patient / care partner input early on during the study design and protocol development can help improve patient experience in clinical trials, reduce patient burden, and increase recruitment, retention, and enrollment rates.
Considerations to Help Action the Opportunity
- Define internal sponsor processes to support patient / care partner engagement early in drug development, including budgetary requirements, contracts, IRB / ethics review, legal and data privacy issues, etc.
- Develop an engagement strategy early in the drug development process outlining the plan for identification of representative samples of patients, engagement method(s), timing of engagement(s), data utilization, sharing, assessment, etc.
- Understand investigator / clinical site perspective (in addition to patient / care partner input) of processes, investments and working practices
- Develop robust communication strategy to share information back to patients / care partners about how feedback influenced protocol design / other study elements and justification for when it was not used
- Understand patients / care partners input on the operational difficulties and the options for patients / care partners that can be included in trial design to overcome these
- Establish early partnerships among patients, sponsors, and investigators / clinical sites to build commitment for ongoing sharing of information
Value and Potential Benefits
- Improves patients’ clinical trial experience, reduces patient burden, and increases enrollment rates through patient-centric study design
- Establishes early connection between patients / participants and clinical development program, product / brand and company
- Improves the representation of diverse patient populations in clinical trials via tailored solutions and focused investments
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
Enough, already: the problem with clinical trial data collection
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
